Zoetis Inc Revenue Growth Rates (ZTS), Current and Historic Growth - CSIMarket
CSIMarket
 


Zoetis Inc   (NYSE: ZTS)
 

ZTS's Revenue Growth by Quarter and Year

Zoetis Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ZTS/growth
https://api.csimarket.com/api/v1/companies/ZTS/fundamentals
https://api.csimarket.com/api/v1/companies/ZTS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
ZTS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2,391.00
2nd Quarter June 2,468.00
1st Quarter March 2,262.00
FY 7,121.00

ZTSs Annual Revenue
Zoetis Inc 's Revenue in the fiscal year 2025 $ 9,467.00 millions
Zoetis Inc 's Revenue in the fiscal year 2024 $ 9,256.00 millions
Zoetis Inc 's Revenue in the fiscal year 2023 $ 8,544.00 millions
Zoetis Inc 's Revenue in the fiscal year 2022 $ 8,080.00 millions
Zoetis Inc 's Revenue in the fiscal year 2021 $ 7,776.00 millions




ZTS Revenue third quarter 2026 Y/Y Growth Comment
Zoetis Inc reported decrease in Revenue in the third quarter 2026 by -0.38% to $ 2,391.00 millions, from the same quarter in 2025.
The decrease in the third quarter 2026 Zoetis Inc 's Revenue compares unfavorably to the Company's average Revenue growth of 6.25%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 133 other companies have achieved higher Revenue growth. While Zoetis Inc ' s Revenue decline of -0.38% ranks overall at the positon no. 2806 in the third quarter 2026.




ZTS Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -0.38 %
2nd Quarter June 0.33 %
1st Quarter March 2.91 %
FY   -

Financial Statements
Zoetis Inc 's third quarter 2026 Revenue $ 2,391.00 millions ZTS's Income Statement
Zoetis Inc 's third quarter 2025 Revenue $ 2,400.00 millions Quarterly ZTS's Income Statement


ZTS Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -3.12 %
2nd Quarter June 9.11 %
1st Quarter March -5.24 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #392
Overall #2806

Revenue Y/Y Growth Statistics
High Average Low
25.84 % 6.25 % -3.48 %
(Jun 30 2021)  
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #134
Healthcare Sector #392
Overall #2806
Revenue Y/Y Growth Statistics
High Average Low
25.84 % 6.25 % -3.48 %
(Jun 30 2021)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Zoetis Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
15.41 % 1.82 % -16.52 %
(Dec 31 2012)  


ZTS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Zoetis Inc disclosed fall in Revenue from the second quarter by -3.12% to $ 2,391.00 millions, from $ 2,468.00 millions achived in the previous reporting period.

But that's not important problem, as Zoetis Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Zoetis Inc 's Revenue growth quarter on quarter, overall rank is 851.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #127
Overall #851
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #55
Healthcare Sector #127
Overall #851
Revenue Q/Q Growth Statistics
High Average Low
15.41 % 1.82 % -16.52 %
(Dec 31 2012)  


ZTS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Zoetis Inc disclosed fall in Revenue from the second quarter by -3.12% to $ 2,391.00 millions, from $ 2,468.00 millions achived in the previous reporting period.

But that's not important problem, as Zoetis Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Zoetis Inc 's Revenue growth quarter on quarter, overall rank is 851.


Zoetis Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 9,517.00
Y / Y Revenue Growth (TTM) 1.64 %
Year on Year Revenue Growth Overall Ranking # 2029
Seqeuential Revenue Change (TTM) 0.08 %
Seq. Revenue Growth (TTM) Overall Ranking # 2521


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Zoetis Inc 's cumulative twelve months Revenue were $ 9,517 millions, company would post below average annual Revenue growth of 0.08% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Zoetis Inc 's Revenue growth from the 2468% growth in Mar 31 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1805 to 2029.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 312
Overall # 2029

Revenue TTM Y/Y Growth Statistics
High Average Low
16.91 %
6.34 %
-0.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2521
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Zoetis Inc 's cumulative twelve months Revenue were $ 9,517 millions, company would post below average annual Revenue growth of -0.42% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Zoetis Inc 's Revenue growth from the 2468% growth in Mar 31 2026.

In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1805 to 2029.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 312
Overall # 2029

Revenue TTM Y/Y Growth Statistics
High Average Low
16.91 %
6.34 %
-0.42 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 366
S&P 500 # 2521




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ZTS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions
Milestone Scientific Inc -5.95%$ -5.948 millions


About Zoetis Inc Revenue Growth Rates (ZTS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Zoetis Inc (CIK 1555280).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001555280-26-000050
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Zoetis Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.